65,437 trials
Endometrial Cancer
Primary: Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System — 15 Participants
Open Heart Surgery
Primary: Percentage of Time Bispectral Index Remains Within 10 of Target BIS of 50 — 75.9; 84.6 percentage of time
Myelofibrosis
Primary: Efficacy of CC-5013 in Myelofibrosis — 7; 9; 12; 9 Participants
Healthy
Primary: Cmax of Donepezil. — 17800.27; 17280.23 ng/mL
Healthy
Primary: Cmax of Fluoxetine. — 64.17; 56.61 ng/mL
Healthy
Primary: Cmax of Venlafaxine. — 124.75; 117.69 ng/mL
HIV Infections
Primary: HIV Viral Load — -0.18; -0.05; 0.002; 0.26 HIV RNA copies/mL — p=0.008
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
Diphtheria · Tetanus
Primary: Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. — 96; 97; 71; 71 Percentage of participants
Colonic Diseases
Primary: Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies — 322; 326 participants
HIV Infections · Tuberculosis
Primary: Number of Participants With Microbiologically Confirmed Pulmonary Tuberculosis — 23 Participants
Acromegaly
Primary: The Percentage of Participants With Complete Response (CR) at 8 Months — 25; 0; 9.4 percent
Actinic Keratosis
Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)…
Myopia · Astigmatism
Primary: Symptoms and Complaints — 79.3; 77.7; 73.5; 71.5 Scores on a Scale